Figure 3: Detection of total anti-HER2/neu immunoglobulin in the form of gemcitabine-(C4-amide)-[anti-HER2/neu] bound to HER2/neu on the exterior surface membrane of chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Covalent gemcitabine-(C4-amide)-[anti-HER2/ neu] immunochemotherapeutic was incubated with monolayer populations of mammary adenocarcinoma (SKBr-3) over a 4-hour period and cell-ELISA was applied to measure total exterior surface membrane bound immunoglobulin.